Fresenius Follows US Denosumab Filing With EU Acceptance

EMA Accepts Firm’s Applications For Biosimilar Rivals To Prolia And Xgeva

 
• By Dave Wallace

Fresenius Kabi’s denosumab biosimilar filing has been accepted by the European Medicines Agency, coming hot on the heels of a US submission.

EMA
Fresenius has filed its denosumab biosimilars with the EMA

More from Biosimilars

More from Products